BMS-754807 / BMS - LARVOL DELTA

Multi-Omics Integration Identifies CDH3-Driven Malignant Progression and Pathology-Based Risk Stratification in Thymic Epithelial Tumors (IASLC-WCLC 2026) - "Drug-sensitivity analyses prioritized BMS-754807 and MK-2206 as candidate agents, both of which showed antitumor activity in xenograft and patient-derived organoid models. Multi-omic and histopathologic analyses identified CDH3 as a biomarker and functional driver of aggressive disease, associated with poor prognosis, genomic instability, and macrophage/fibroblast-rich microenvironments. Functional and pharmacologic evidence further supported CDH3 as a potentially targetable mediator of aggressive TET biology, with pharmacologic inhibition showing antitumor effects in xenograft and organoid models."

Oncology • Solid Tumor • Thymic Carcinoma • Thymic Epithelial Tumor • Thymus Cancer • CDH3 • CTGF • LRP1 • TGFB1 • VIM

Identification of potential vinorelbine-associated prognostic genes in breast cancer through integrative bioinformatics and experimental validation. (PubMed, Front Oncol) - "AZD1332_1463, BMS.754807_2171, mitoxantrone_1810, and nutlin.3a…._1047 had significantly positive correlations with the risk score. RT-qPCR analysis revealed significantly higher expressions of TGFB1 and BRCA1 in BC samples compared to BC-VLB+PD samples, while IL7 and PTGS2 expressions were significantly lower in BC samples. This study identified TUBA1C, BRCA1, TGFB1, TUBA1B, XRCC1, PTGS2, IL7, and TUBB2B as prognostic genes for breast cancer that are potentially associated with vinorelbine treatment, offering actionable biomarkers for individualized prognosis assessment and guiding patient stratification for vinorelbine-based combination therapies in clinical practice."

Journal • Breast Cancer • Oncology • Solid Tumor • BRCA1 • IL7 • PACERR • PTGS2 • TGFB1 • TUBA1B • TUBA1C • TUBB2B • XRCC1

Expression characteristics analysis, establishment of prognostic model and screening of key regulators based on selenium protein-related genes in rectal adenocarcinoma. (PubMed, J Trace Elem Med Biol) - "The dysregulation of selenium-related genes may be associated with the progression of READ, and they are helpful for READ patients stratification. Selenium supplementation may exert anti-tumor effects by regulating oxidative stress and cell cycle. Selenium-related proteins are potential biomarkers and candidate targets for READ."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • PTGS1 • SELENOP

GLOBAL ALTERATIONS IN 3D DNA ARCHITECTURE DRIVE UNIQUE LEUKEMOGENIC PROFILES IN IDH1- AND DNMT3A-MUTANT ACUTE MYELOID LEUKEMIA (EHA 2026) - "While IGF1R upregulation corresponded to in-vitro sensitivity of IDH1 -mut KG1a to IGF1R inhibitor BMS-754807 as mono- and combinational therapy with ivosidenib tested by WST1 assay, loop-mediated transcriptional dysregulation of trafficking regulator TBC1D16 in DNMT3A -mut AML was associated with sensitivity to the p38 MAKP inhibitor ralimetinib. Summary/Conclusion Taken together, our data demonstrate genotype-specific 3D-genome reorganization that alters transcription and signaling in IDH1 - or DNMT3A -mut AML and identified targetable candidates for both entities, highlighting the role of 3D-DNA alteration as global driver of leukemogenesis in AML with epigenetic mutations."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • DNMT3A • ETS1 • EXT1 • IDH1 • IGF1R • IKZF3 • IRS2 • SEPTIN9

Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin. (PubMed, Front Endocrinol (Lausanne)) - "We found that IGF-1 stimulation increased MDA-MB-231 TNBC adhesion, which was reversed by the IGF1R tyrosine kinase inhibitor BMS-754807 and the ligand-dependent receptor internalization inhibitor dansylcadaverine...This model is supported further by our finding that treatment of MDA-MB-231 cells with dansylcadaverine, which inhibits ligand-mediated receptor internalization, blocked the effect of IGF-1 on adhesion. These findings further elucidate IGF1R function during breast cancer metastasis by modulating cell adherence."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • IGF1

Identification of a novel ion channel-related gene signature to predict prognosis and immune response of gastric cancer. (PubMed, Transl Cancer Res) - "Evaluations of immune infiltration patterns and drug susceptibility in cohorts stratified by high versus low ICRGRS revealed that elevated ICRGRS instances featured an immunosuppressive tumor microenvironment and displayed superior gains from ZM447439, RO-3306, NU7441, BMS-754807, and JQ1. On the other hand, low-ICRGRS cases showed increased efficacy toward immunotherapies and conventional GC agents like Oxaliplatin and 5-fluorouracil...CNGB3 knockdown significantly suppressed the malignant phenotype of GC cells. Our findings furnish innovative viewpoints on outcome forecasting and therapeutic targets of GC through the lens of ion channels."

Gene Signature • IO biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor

The insulin receptor inhibitor BMS-754807 alleviates neuroinflammation and Alzheimer's disease pathologies across human cellular and mouse models. (PubMed, J Neuroinflammation) - "Taken together, our results suggest that BMS-754807 exerts anti-inflammatory and potential disease-modifying effects by attenuating LPS/Aβ/tau-evoked glial activation and reducing Aβ and tau pathologies in both human cellular and mouse models of neuroinflammation and AD. Furthermore, BMS-754807 administration improved specific domains of cognitive function in vivo. These findings support pharmacological inhibition of IGF-1R as a potential therapeutic approach for neuroinflammation-associated diseases including AD."

Journal • Preclinical • Alzheimer's Disease • Breast Cancer • CNS Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammation • Oncology • Solid Tumor • Aβ42 • HER-2 • IR • NLRP3

Leveraging mitochondrial dynamics-related risk signatures to predict the prognosis and tumor microenvironment of lung adenocarcinoma. (PubMed, Discov Oncol) - "This work set up a prognostic model for LUAD based on 8 MDRGs, pinpointing promising biomarkers and targets for LUAD treatment."

Biomarker • Journal • Tumor mutational burden • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CYP27A1 • HMGA2 • SLC2A3 • TMB

Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes. (PubMed, Front Med (Lausanne)) - "Drugs like VX.702 and BMS.754807 were more effective in the high-risk group...ESCC tumor tissues exhibited markedly decreased AMN and ERICH5 expression but increased HRG compared to normal controls. This study identified prognostic signature genes associated with CRT and PS in ESCC and constructed a risk model that may predict patient survival, which could provide valuable insights for future research on ESCC diagnosis and treatment."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • ANXA10

Unveiling disulfidptosis-linked lncRNA signatures: insights into the immune microenvironment and drug responsiveness in oral squamous cell carcinoma. (PubMed, Front Genet) - "12 drugs were identified for OSCC treatment, such as BMS-754807_2171 and Foretinib_2040. Our study identified 9 DE-DRLs correlated with OSCC, which will be a personalized prediction tool for prognosis and immune responses in OSCC patients."

Journal • Tumor mutational burden • Oncology • Oral Cancer • Squamous Cell Carcinoma • CD4 • TMB

Exploratory Analysis of Regulated Cell Death-Related Genes as Potential Prognostic Biomarkers in Endometrial Carcinoma. (PubMed, Biomedicines) - "Based on sensitivity analysis of chemotherapeutic agents, we found the highest positive correlation between SLC11A1 and "BI.2536" and the strongest passive correlation of HCLS1 and GBP2 with "Ribociclib", as well as P2RX7 with "BMS.754807". Quantitative real-time polymerase chain reaction suggested that the expression trends of GBP2, P2RX7, and HCLS1 were consistent with the results of bioinformatic analysis. Regulated cell death-related genes (GBP2, SLC11A1, P2RX7, and HCLS1) may play a role in endometrial carcinoma development, which can provide new ideas for the treatment and prognosis prediction of this disease."

Biomarker • IO biomarker • Journal • Endometrial Cancer • Oncology • Solid Tumor • CD8 • GBP2 • SLC11A1 • TIGIT

Insulin-Like Growth Factor 1 Receptor Regulates Breast Cancer Cell Adhesion through Beta-1 Integrin. (PubMed, bioRxiv) - "We found that IGF-1 stimulation increased MDA-MB-231 TNBC adhesion, which was reversed by the IGF1R tyrosine kinase inhibitor BMS-754807 and the ligand-dependent receptor internalization inhibitor dansylcadaverine...This model is supported further by our finding that treatment of MDA-MB-231 cells with dansylcadaverine, which inhibits ligand-mediated receptor internalization, blocked the effect of IGF-1 on adhesion. These findings may explain why selective IGF1R receptor antagonists, which downregulate IGF1R protein upon chronic administration, were unsuccessful in the clinical setting."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • IGF1

Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer. (PubMed, Clin Exp Med) - "BMS-754807, Gefitinib, JQ1, Lapatinib, and Sapitinib exhibited significant differences in sensitivity between the high-risk group and the low-risk group. The results of molecular docking showed TP8A2 has stable binding ability with cytosine, COX15 with indomethacin, and TARS2 with bisacodyl. RT-qPCR revealed downregulation of ATP8A2 and upregulation of COX15 and TARS2 in GC samples. MNGs, including ATP8A2, COX15, and TARS2, demonstrated significant associations with immune infiltration, CNV, and prognostic outcomes of GC."

Biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor

A prognostic model for multiple myeloma based on lipid metabolism related genes. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "LRGs serve as promising biomarkers for prognosis prediction and risk stratification in MM. The overexpression of chromosomal instability-related and high-risk genetic event-associated genes in high-risk patients may explain their poorer outcomes. Given the observed resistance to bortezomib and lenalidomide in high-risk patients, combination therapies involving BMS-754807 or I-BET-762 may represent effective alternatives."

Journal • Hematological Disorders • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Oncology • B2M • FGFR3

Migrasome-Related Prognostic Genes in Gastric Cancer: A Transcriptomic and Immunotherapeutic Analysis. (PubMed, Onco Targets Ther) - "Immune profiling showed distinct microenvironment features in high-risk groups, along with differential sensitivity to specific chemotherapeutic agents (eg, BMS-754807)...The established risk model provides novel molecular markers and potential therapeutic targets for personalized GC treatment. These findings offer critical insights for understanding GC pathogenesis and developing innovative treatment strategies."

IO biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor • TGFB1 • TGFB2 • WNT11

Comprehensive analysis of prognosis and drug sensitivity of programmed cell death pattern-related genes in gastric cancer patients. (PubMed, Sci Rep) - "Furthermore, the CDI risk score exhibited positive correlations with most drugs (except for BMS.754807). Additionally, the expression of immune checkpoint genes PDCD1, CD274, and IDO1 was notably upregulated in the low-risk CDI group. Our developed CDI model, based on 17 PCD-associated prognostic genes, can be employed for risk assessment and prognosis prediction in patients with GC."

Biomarker • IO biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor • IDO1 • IL17A • PD-1 • PD-L1

Integrative Pharmacogenomics in RCC Tumoroids Uncovers Biomarker-Driven Combination Therapies (EACR 2025) - "Scaffold-free tumoroids faithfully recapitulate interpatient heterogeneity in RCC, serving as robust platforms for drug discovery. Our pharmacogenomic framework identifies actionable therapeutic vulnerabilities and predictive biomarkers, providing a rationale for personalized combination therapies."

Biomarker • Combination therapy • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IR

Machine Learning and Weighted Gene Coexpression Network-Based Identification of Biomarkers Predicting Immune Profiling and Drug Resistance in Lung Adenocarcinoma. (PubMed, Int J Genomics) - "The drug sensitivity study showed that patients in the high-risk group had higher IC50 values for BMS-754807_2171 and Doramapimod_10424. Finally, in vitro experiments demonstrated that knocking down ANLN noticeably inhibited the viability, migration, and invasion of A549 cells. This study may provide a theoretical reference for future exploration of potential diagnostic and prognostic biomarkers for LUAD."

Biomarker • IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ANLN • NMUR1

Construction of CD8+ T Cell-Associated Risk Model in Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA-Seq Data (APASL 2025) - "BMS-754807, Gemcitabine, et al exhibited sensitive to patients in low-risk group, AZD6482 and SB505124 may serve as novel potential targeted drugs for patients in high-risk group. A CD8+ T cell-associated risk scoring model consisting of KLRB1, RGS2 and TNFRSF1B has been developed to predict prognosis and provide potential drugs for HCC treatment. Table and Figure:Figure 1."

IO biomarker • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • CD8 • KLRB1 • RGS2 • TNFRSF1B

Prognostic value of disulfidptosis-associated genes in gastric cancer: a comprehensive analysis. (PubMed, Front Oncol) - "Potentially effective drugs, including BMS-754807, dabrafenib, and JQ1, were identified. This study developed a novel prognostic model for gastric cancer using DRLs, identifying two key signaling axes related to prognosis. JQ1 may be an effective treatment, and FRMD6-AS could be a promising therapeutic target."

Journal • Tumor mutational burden • Cardiovascular • Gastric Cancer • Oncology • Solid Tumor • FRMD6 • TLN1 • TMB

Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis. (PubMed, Oncol Lett) - "Drug sensitivity analysis revealed that the high-risk group exhibited increased sensitivity towards vinblastine, docetaxel and cisplatin, whereas the low-risk group showed increased sensitivity to BMS_754807, SB505124_1194 and JQ1_2172. In conclusion, a KNHMUGs-based gene signature was constructed in the present study, which holds promise as a biomarker for evaluating patient prognosis and guiding treatment by effectively assessing immunotherapy response and chemotherapy sensitivity in patients with LUAD."

IO biomarker • Journal • Hepatology • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BTLA • CD4 • CD8 • CTLA4 • HAVCR2 • HMOX1 • KEAP1 • KYNU • TIGIT

NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis. (PubMed, Sci Rep) - "Sensitivity analysis of chemotherapy drugs showed that NOS2 was significantly correlated with several chemotherapy drugs, such as MG.132_1862, BMS.754807_2171, and GEN.317_1926. Clinical validation analysis showed that the expression of NOS2 and its related genes CXCL1 and CXCL2 were significantly decreased in EOCRC patients. The results suggested that NOS2 can be used as a potential biomarker for EOCRC, which can be used for prognosis and guidance of immunotherapy and chemotherapy."

Biomarker • IO biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • CXCL1 • NOS2

Revolutionizing prognosis: Introducing cell death index (CDI) as a powerful prognostic tool for CSCC patients. (PubMed, Environ Toxicol) - "This investigation constructed a novel effective prognostic indicator of CDI in patients with CSCC and identified potential genes associated with cell death that could be targeted for prognosis and treatment of CSCC."

Journal • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Identification of Hepatocellular Carcinoma Subtypes Based on Global Gene Expression Profiling to Predict the Prognosis and Potential Therapeutic Drugs. (PubMed, Biomedicines) - "Subtype S1 appeared to be more sensitive to BMS-754807, JQ1, and Axitinib, while subtype S2 was more sensitive to SB505124, Pevonedistat, and Tamoxifen. HCC patients can be classified into two subtypes based on their gene expression profiles, which exhibit distinctions in terms of signaling pathways, the immune microenvironment, and drug sensitivity."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • COL11A1 • COL1A1

Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study. (PubMed, Mol Med) - "The CDI-based model, which was established using 14 PCD-related genes, accurately predicted the tumor microenvironment, immunotherapy response, and drug sensitivity of patients with SOC. Thus this model may help improve the diagnostic and therapeutic efficacy of PPPM."

Biomarker • IO biomarker • Journal • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor